ICER's assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine.

Franklin, Meg; Druyts, Eric · J Manag Care Spec Pharm · 2020

editorial · Level V

Where this comes from

Abstract

<b>DISCLOSURES:</b> No funding supported the writing of this commentary. The authors have nothing to disclose.

Medical subject headings